elieves that NVC-422 may deliver the same or better efficacy as currently used antibiotics without giving rise to resistant bacteria. In past in-vitro
studies, NVC-422 has shown a broad therapeutic index with broad spectrum activity against bacteria of all types, including multidrug resistant species, shedding viruses including adenoviruses and herpes viruses, yeasts and fungi. In addition, NVC-422 has previously shown, in-vivo
, to be safe at expected therapeutic doses in the nose, bladder, wounds and eye. NVC-422 is protected by U.S. Patent #7,462,361 until 2026. In addition to Alcon's development in the eye, NovaBay has taken NVC-422 into Phase II human trials for infections in the nose and bladder and expects to begin a Phase II trial for the treatment of skin infections, including those caused by MRSA (Methicillin resistant Staphylococcus aureus), in 2009.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a clinical stage biopharmaceutical company developing first-in-class, novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without developing resistance. NovaBay has entered into a licensing and research collaboration agreement with Alcon, Inc. for use of the Aganocide compounds in the eye, ear and sinus, and in contact lens solutions. NovaBay(R) and Aganocide(R) are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit www. novabaypharma.com.
Cautionary Information Regarding Forward-Looking Statements
The statements in this press release regarding the potential efficacy of NVC-422 and NovaBay's expectation to begin a Phase II trial for the treatment of skin infections in 2009 are forward-looking statements. These statements are subject to risks and uncertainties that could cau
Page: 1 2 3 Related medicine news :1
|SOURCE NovaBay Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock2
. NovaBay announces third quarter 2007 financial results3
. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference4
. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet5
. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma6
. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences7
. Vista Partners Updates Coverage on Tapestry Pharmaceuticals8
. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference9
. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.10
. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes11
. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs